June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Can Serum Drops Containing Doxycycline Provide Potential Anti-Bacterial Effect in the Treatment of Bacterial Keratitis?
Author Affiliations & Notes
  • David Mora-Boellstorff
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, UPMC, Pittsburgh, Pennsylvania, United States
  • Kanwal Matharu
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, UPMC, Pittsburgh, Pennsylvania, United States
  • Vishal Jhanji
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, UPMC, Pittsburgh, Pennsylvania, United States
  • Regis P Kowalski
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, UPMC, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   David Mora-Boellstorff None; Kanwal Matharu None; Vishal Jhanji None; Regis Kowalski None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3240 – A0275. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Mora-Boellstorff, Kanwal Matharu, Vishal Jhanji, Regis P Kowalski; Can Serum Drops Containing Doxycycline Provide Potential Anti-Bacterial Effect in the Treatment of Bacterial Keratitis?. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3240 – A0275.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Systemic doxycycline has been prescribed to enhance corneal healing in the setting of bacterial keratitis. Topical autologous serum drops containing doxycycline via oral supplementation may additionally confer an anti-bacterial effect. The potential of this treatment supplementation was evaluated by determining the in vitro susceptibility of bacterial keratitis isolates to doxycycline.

Methods : The minimum inhibitory concentrations (MICs) to doxycycline of 100 bacterial keratitis isolates submitted to the Charles T. Campbell Ophthalmic Microbiology Laboratory at the University of Pittsburgh Medical Center were determined using Etests. Twenty-seven (27%) Staphylococcus aureus, 10 (10%) coagulase-negative Staphylococci, 6 (6%) Streptococcus pneumoniae, 7 (7%) Streptococcus viridans group, 7 (7%) other Gram-positive bacteria, 19 (19%) Pseudomonas aeruginosa, 8 (8%) Serratia marcescens, 4 (4%) Moraxella spp., 2 (2%) Haemophilus spp., and 10 (10%) other Gram-negative bacteria isolates were tested. MICs to doxycycline were compared to a serum standard concentration of doxycycline (SD) of 4 µg/ml as well as concentrations of doxycycline in serum drops at 50% SD (2 µg/ml) and 20% SD (0.8 µg/ml) as would be found in clinical preparations of autologous serum 50% and 20% drops, respectively. MICs equal or less than these values were deemed susceptible.

Results : For Gram-positive bacteria, susceptibilities to SD, 50% SD, and 20% SD were respectively, 86%, 65%, and 60%. For Staphylococcus aureus, susceptibilities to SD, 50% SD, and 20% SD were respectively, 92.6%, 85.2%, and 77.8%. For Gram-negative bacteria, susceptibilities to SD, 50% SD, and 20% SD were respectively, 37.2%, 23.3%, and 11.6%. Pseudomonas aeruginosa tested resistant to doxycycline at all concentrations. For the composite dataset of bacterial keratitis isolates, susceptibilities to SD, 50% SD, and 20% SD were respectively, 65%, 47%, and 39%. Chi-squared analyses comparing Gram-positive and Gram-negative susceptibilities showed significantly greater susceptibility of Gram-positive bacteria at all three tested MICs (<.0001, <.0001, <.0001).

Conclusions : Our data suggests that serum drops containing doxycycline may have a select advantage for treating Gram-positive bacterial keratitis, especially Staphylococcus aureus, over Gram-negative bacterial keratitis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×